Concepedia

Once-weekly Formulations

Once-Weekly Formulations is a pharmaceutical delivery strategy within the class of glucagon-like peptide-1 receptor agonists distinguished by its design for sustained release and therapeutic efficacy with a dosing interval of once per week, thereby enhancing patient adherence and convenience compared to more frequent regimens.

189

Publications

16.9K

Citations

1.3K

Authors

591

Institutions

Publications per year

2017–2026

79

Parents

Publications

189

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

Rury R. Holman, M. Angelyn Bethel, Robert J. Mentz et al. · New England Journal of Medicine · 2017 · 2.1K citations · Full text

, , +14

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

Jesper Lau, Paw Bloch, Lauge Schäffer et al. · Journal of Medicinal Chemistry · 2015 · 1K citations · Full text

, , +17

Once-Weekly Semaglutide in Adolescents with Obesity

Daniel Weghuber, Timothy Barrett, Margarita Barrientos‐Pérez et al. · New England Journal of Medicine · 2022 · 638 citations · Full text

, , +15

Clinical Evaluation of Once-Weekly Dosing of Epoetin Alfa in Chemotherapy Patients: Improvements in Hemoglobin and Quality of Life Are Similar to Three-Times-Weekly Dosing

Janice Gabrilove, Charles S. Cleeland, Robert B. Livingston et al. · Journal of Clinical Oncology · 2001 · 596 citations

, , +14

DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes

Thomas Blevins, John Pullman, Jaret Malloy et al. · The Journal of Clinical Endocrinology & Metabolism · 2011 · 446 citations · Full text

, , +17

1–5 of 189

Authors

1.3K

  1. JR
    Julio Rosenstock

    Dallas Diabetes Research Center, United States

    9 publications · 1K citations

    9

    h-index

  2. AC
    Andrei‐Mircea Catarig

    Novo Nordisk (Denmark), Denmark

    6 publications · 597 citations

    6

    h-index

  3. MT
    Michael Trautmann

    Eli Lilly (United States), United States

    6 publications · 1.1K citations

    6

    h-index

  4. JM
    Jaret Malloy

    Lawson Health Research Institute, Canada

    6 publications · 727 citations

    6

    h-index

  5. MA
    Michael A. Nauck

    Diabeteszentrum Bad Lauterberg, Germany

    5 publications · 563 citations

    5

    h-index

1–5 of 1.3K

Institutions

591

  1. Novo Nordisk (Denmark)

    Copenhagen, Denmark

    25 h-index

    103 publications

    27K citations

  2. Eli Lilly (United States)

    Indianapolis, United States

    17 h-index

    47 publications

    4.3K citations

  3. AstraZeneca (United States)

    Wilmington, United States

    7 h-index

    19 publications

    9.3K citations

  4. Bristol-Myers Squibb (United States)

    New York, United States

    6 h-index

    6 publications

    242 citations

  5. Dallas Diabetes Research Center

    Dallas, United States

    6 h-index

    6 publications

    643 citations

  6. Profil Institute for Metabolic Research

    Neuss, Germany

    6 h-index

    11 publications

    654 citations

  7. Roche (Switzerland)

    Basel, Switzerland

    6 h-index

    13 publications

    771 citations

  8. Pfizer (United States)

    New York, United States

    5 h-index

    18 publications

    1.4K citations

1–8 of 591

Venues

  1. Diabetes Obesity and Metabolism

    19 publications · 1.4K citations

    19

    h-index

  2. Diabetes Care

    9 publications · 1.5K citations

    9

    h-index

  3. Diabetes Therapy

    8 publications · 306 citations

    8

    h-index

  4. The Journal of Clinical Endocrinology & Metabolism

    JCEM · 8 publications · 852 citations

    8

    h-index

  5. PubMed

    Repository · 8 publications · 264 citations

    7

    h-index

1–5